CN109152837A - 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 - Google Patents

用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 Download PDF

Info

Publication number
CN109152837A
CN109152837A CN201780029157.9A CN201780029157A CN109152837A CN 109152837 A CN109152837 A CN 109152837A CN 201780029157 A CN201780029157 A CN 201780029157A CN 109152837 A CN109152837 A CN 109152837A
Authority
CN
China
Prior art keywords
initiator
dose
dosage
medicament
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780029157.9A
Other languages
English (en)
Chinese (zh)
Inventor
欧文·L·唔斯曼
马克·P·超
拉温德拉·玛吉特
刘劼
延斯-皮特·福尔克默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CN202311544173.5A priority Critical patent/CN117695387A/zh
Priority to CN202210926503.6A priority patent/CN115350276A/zh
Publication of CN109152837A publication Critical patent/CN109152837A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780029157.9A 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 Pending CN109152837A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311544173.5A CN117695387A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202210926503.6A CN115350276A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US62/323,330 2016-04-15
US201662427679P 2016-11-29 2016-11-29
US62/427,679 2016-11-29
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311544173.5A Division CN117695387A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202210926503.6A Division CN115350276A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Publications (1)

Publication Number Publication Date
CN109152837A true CN109152837A (zh) 2019-01-04

Family

ID=60042716

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201780029157.9A Pending CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202210926503.6A Pending CN115350276A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202311544173.5A Pending CN117695387A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210926503.6A Pending CN115350276A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202311544173.5A Pending CN117695387A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Country Status (12)

Country Link
US (3) US11472878B2 (https=)
EP (3) EP3442578B1 (https=)
JP (3) JP7532009B2 (https=)
KR (3) KR102505253B1 (https=)
CN (3) CN109152837A (https=)
AU (2) AU2017250809B2 (https=)
CA (1) CA3019676A1 (https=)
ES (1) ES2909835T3 (https=)
PL (1) PL3442578T3 (https=)
PT (1) PT3442578T (https=)
SI (1) SI3442578T1 (https=)
WO (1) WO2017181033A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
JP7308191B2 (ja) 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７剤ベースの卵巣癌療法
CN111699005A (zh) * 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
JP2021529219A (ja) * 2018-07-05 2021-10-28 トリカン・バイオテクノロジー・カンパニー・リミテッドＴｒｉｃａｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ ヒト抗ｃｄ４７抗体およびその使用
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
EP3886869A4 (en) 2018-11-28 2022-07-06 Forty Seven, Inc. GENETICALLY MODIFIED ABLATION-RESISTANT HSPCS
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
WO2022076928A1 (en) * 2020-10-09 2022-04-14 Sana Biotechnology, Inc. METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT
US12071481B2 (en) 2020-12-23 2024-08-27 D-10 Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
JP2024503822A (ja) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2014160753A1 (en) * 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2014179132A1 (en) * 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205280B1 (en) * 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
AU2009210741A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
KR102100388B1 (ko) 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
NZ710695A (en) 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
WO2015189698A2 (en) * 2014-06-08 2015-12-17 Beijing Cosci-Remd Bio Med Tech Company Ltd Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
EP3204420B1 (en) * 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
KR20220163447A (ko) * 2020-04-06 2022-12-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체 제형

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
WO2014160753A1 (en) * 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2014179132A1 (en) * 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIE LIU 等: "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential", 《PLOS ONE》 *
OLA STERNEBRING 等: "A Weighted Method for Estimation of Receptor Occupancy for Pharmacodynamic Measurements in Drug Development", 《CYTOMETRY PART B》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂

Also Published As

Publication number Publication date
JP7442591B2 (ja) 2024-03-04
US20190106491A1 (en) 2019-04-11
ES2909835T3 (es) 2022-05-10
SI3442578T1 (sl) 2022-05-31
PT3442578T (pt) 2022-05-19
US11472878B2 (en) 2022-10-18
PL3442578T3 (pl) 2022-06-20
CN115350276A (zh) 2022-11-18
JP7532009B2 (ja) 2024-08-13
KR20240016445A (ko) 2024-02-06
JP2024059764A (ja) 2024-05-01
EP4349412A3 (en) 2024-06-12
EP4074339A1 (en) 2022-10-19
US20230068235A1 (en) 2023-03-02
EP3442578B1 (en) 2022-02-09
AU2017250809A1 (en) 2018-10-25
WO2017181033A1 (en) 2017-10-19
AU2017250809B2 (en) 2024-02-29
EP4349412A2 (en) 2024-04-10
EP3442578A1 (en) 2019-02-20
KR20230035435A (ko) 2023-03-13
CA3019676A1 (en) 2017-10-19
US11718670B2 (en) 2023-08-08
AU2024203396A1 (en) 2024-06-06
KR102505253B1 (ko) 2023-03-02
JP2022172278A (ja) 2022-11-15
JP2019515899A (ja) 2019-06-13
KR20180134367A (ko) 2018-12-18
CN117695387A (zh) 2024-03-15
EP3442578A4 (en) 2019-04-10
US20230406923A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
CN109152837A (zh) 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
AU2020264334B2 (en) Targeted therapy for small cell lung cancer
CN108969763A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
US20240293564A1 (en) Localized delivery of anti-fugetactic agent for treatment of cancer
Facca et al. Adjuvant auger electron-emitting radioimmunotherapy with [111In] in-DOTA-Panitumumab in a mouse model of local recurrence and metastatic progression of human triple-negative breast cancer
Chaikin et al. Hemangiosarcoma in a dog: unusual presentation and increased survival using a complementary/holistic approach combined with metronomic chemotherapy
US12180300B2 (en) Targeting moiety-drug grafted immune cell compositions and methods of use
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40108467A (zh) 用於确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
Nair et al. Midkine as a therapeutic node in NF1-driven neuro‑oncology: Biology, biomarkers, and translational strategies
WO2025172530A1 (en) COMBINATION OF ANTI-PLATELET THERAPY ANTI-GPIbα WITH IMMUNOTHERAPY FOR CANCER
WO2026074471A1 (en) Combination therapies with hafnium oxide nanoparticles and pd-l1 antibodies for use in the treatment of non small cell lung cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination